Home → E-shop → Nucleotides → Mizoribine diphosphate

Mizoribine diphosphate

Mizoribine diphosphate is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Mizoribine diphosphate Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg		€ 5000	Stock
Do you want custom amount?				Custom amount

Amount

1 mg

€ 5000

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: N.A.

IUPAC name: ((2R,3S,4R,5R)-5-(4-carbamoyl-5-hydroxy-1H-imidazol-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl trihydrogen diphosphate

Other names: bredinin diphosphate; MZB diphosphate

Molecular weight: 419.18 g/mol

Molecular formula: C₉H₁₅N₃O₁₂P₂

InChI: InChI=1S/C9H15N3O12P2/c10-7(15)4-8(16)12(2-11-4)9-6(14)5(13)3(23-9)1-22-26(20,21)24-25(17,18)19/h2-3,5-6,9,13-14,16H,1H2,(H2,10,15)(H,20,21)(H2,17,18,19)/t3-,5-,6-,9-/m1/s1

Description

Mizoribine diphosphate is the metabolite of drug Mizoribine (brand name Bredinin) that is used as an immunosuppressive drug. Mizoribine (MZB) is an imidazole nucleoside that has been used in renal transplantation, and in steroid-resistant nephrotic syndrome, IgA nephropathy, lupus, as well as for adults with rheumatoid arthritis, lupus nephritis and other rheumatic diseases

Chemicals are distributed worldwide

Buy Mizoribine diphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Yokota, S. (2002). Mizoribine: mode of action and effects in clinical use. Pediatrics international, 44(2), 196-198.
Turka, L. A., Dayton, J., Sinclair, G., Thompson, C. B., & Mitchell, B. S. (1991). Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. The Journal of clinical investigation, 87(3), 940-948.